Canada

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial – CNBC

2 days ago
1 Views
1 Min Read
  1. Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial  CNBC
  2. Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing  Intellia Therapeutics
  3. Intellia begins FDA filing for CRISPR therapy lonvo-z for rare disease  Investing.com Canada
  4. Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026  Yahoo Finance
  5. Intellia reports positive Phase 3 trial results for HAE therapy By Investing.com  Investing.com Canada

Add Comment

Click here to post a comment